ClinicalTrials.gg
CompletedNCT01924767Updated Jul 4, 2014Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

A Phase 1 interventional study of BI 10773 Placebo and BI 10773 in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-04.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
85th of 130
48 · median 79
Started
2007
the only one that year
Phase 1
24 of 130
5 open now
Registered
30th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 85th largest by enrollment, is the only one that started in 2007, is one of 24 in phase 1, and was the 30th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing, including dose proportionality and assessment of steady state.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and or hysterectomised female patients with proven diagnosis of type 2 diabetes mellitus treated with diet and exercise only or on a maximum of two oral antidiabetic agents except thiazolidindiones with at least one agent taken at 50% of its maximum dose or less.
  2. Glycosylated A1 () £ 8.5 % at screening.
  3. Age >21 and Age \<70 years (male and hysterectomised female patients) Age >60 and Age \<70 years (postmenopausal female patients)
  4. (BMI) >18.5 and \<40 kg/m2
  5. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation

Exclusion criteria

Exclusion criteria:

  1. Antidiabetic treatment with insulin or glitazones or with more than one oral hypoglycaemic agent (except if 2 agents and at least one of them not taken at more than 50% of its maximum dose)
  2. Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) on two consecutive days during washout.
  3. Glycosylated A1 () >8.5% at screening
  4. concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension, such as:

    • Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative disorders, diabetic foot)
    • Renal insufficiency (calculated \< 80 ml/min/1.73m²)
    • Cardiac insufficiency II-IV, myocardial infarction, other known cardiovascular diseases including hypertension > 160/95mmHg (measured at training visit and each of the timepoints of Day -1), stroke and (Transistoric ischaemic attack)
    • Neurological disorders (such as epilepsy) or psychiatric disorders
    • Acute or relevant chronic infections (e.g. , repeated urogenital infections)
    • Any gastrointestinal, hepatic, respiratory, endocrine or immunological disorder
  5. History of relevant allergy/ (including allergy to drug or its )
  6. A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  7. A history of additional risk factors for TdP (torsade des pointes) (e.g., heart failure, hypokalemia, family history of sudden death before the age of 50)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
48 participants (actual)

Study arms

  • Experimental
    BI 10773 (dose group 3)

    multiple doses as tablet

    Drug: BI 10773 Placebo · Drug: BI 10773

  • Experimental
    BI 10773 (dose group 4)

    multiple doses as tablet

    Drug: BI 10773 · Drug: BI 10773 Placebo

  • Experimental
    BI 10773 (dose group 1)

    multiple doses as tablet

    Drug: BI 10773 Placebo · Drug: BI 10773

  • Experimental
    BI 10773 (dose group 2)

    multiple doses as tablet

    Drug: BI 10773 Placebo · Drug: BI 10773

Interventions

  • DrugBI 10773 Placebo

    po taken fasting with 240 mL water

  • po taken fasting with 240 mL water

  • DrugBI 10773 Placebo

    po taken fasting with 240 mL water

  • po taken fasting with 240 mL water

  • DrugBI 10773 Placebo

    po taken fasting with 240 mL water

  • DrugBI 10773 Placebo

    po taken fasting with 240 mL water

  • po taken fasting with 240 mL water

  • po taken fasting with 240 mL water

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests

    Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).

    Time frame: day 1 to day 21

  2. Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results

    Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results

    Time frame: day 1 to day 21

  3. Micturition Frequency

    Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.

    Time frame: Baseline and Day 9

  4. Assessment of Tolerability by Investigator

    Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.

    Time frame: day 21

Secondary outcomes

  1. Concentration of the Analyte in Plasma

    Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  2. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)

    AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  3. Time to Maximum Concentration of the Analyte in Plasma

    Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  4. Terminal Rate Constant in Plasma

    Terminal rate constant in plasma after first dose and at steady-state

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  5. Half-life and Mean Residence Time of the Analyte in Plasma

    Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  6. Apparent Volume of Distribution During the Terminal Phase

    Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  7. Amount of Analyte Eliminated in Urine

    Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)

    Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9

  8. Fraction of Analyte Excreted Unchanged in Urine

    Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.

    Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9

  9. Apparent and Renal Clearance of the Analyte in Plasma

    Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  10. Peak Trough Fluctuation

    Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  11. Linearity Index

    The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  12. Accumulation Ratios

    Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau

    Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.

  13. Change From Baseline to Day 8 in Urinary Glucose Excretion

    Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.

    Time frame: -2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8

  14. Mean Daily Glucose

    Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.

    Time frame: 0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8

  15. Fasting Plasma Glucose

    Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.

    Time frame: -0:30 (Pre dose samples)

  16. Serum Insulin

    Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.

    Time frame: 0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8

  17. Serum Insulin

    Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)

    Time frame: 0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8

07

Results

Posted Jul 4, 2014

Participant flow

This Phase I trial was randomised, double-blind, and placebo-controlled within dose groups. It was to be performed in 48 female and male patients with type 2 diabetes in 4 sequential groups of 12 patients each. Within each dose group, 9 patients were to receive active drug and 3 were to receive placebo.

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Started129999
Completed119899
Not completed10100
Withdrew: Adverse event10100

Outcome measures

PrimaryPercentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests

Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).

Time frame:
day 1 to day 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
percentage of participantsPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Cardiac disorders0.00.00.00.00.0
Investigations: Hepatic enzyme increased8.30.00.00.00.0
PrimaryPercentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results

Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results

Time frame:
day 1 to day 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results
percentage of participantsPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Clinically relevant0.00.00.00.00.0
Clinically irrelevant100.0100.0100.0100.0100.0
PrimaryMicturition Frequency

Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.

Time frame:
Baseline and Day 9
Reported as:
Mean · frequency of micturition
Micturition Frequency
frequency of micturitionPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Micturition day frequency4.1 ± 1.82.6 ± 2.15.0 ± 1.63.9 ± 1.54.4 ± 2.1
Micturition night frequency0.3 ± 1.60.2 ± 1.20.5 ± 0.50.6 ± 1.60.7 ± 0.9
Micturition total frequency4.5 ± 2.12.8 ± 2.65.5 ± 1.54.4 ± 2.45.1 ± 2.2
PrimaryAssessment of Tolerability by Investigator

Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.

Time frame:
day 21
Reported as:
Number · percentage of participants
Assessment of Tolerability by Investigator
percentage of participantsPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Good91.7100.0100.0100.0100.0
Satisfactory0.00.00.00.00.0
Not satisfactory0.00.00.00.00.0
Bad8.30.00.00.00.0
SecondaryConcentration of the Analyte in Plasma

Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · nmol/L
Concentration of the Analyte in Plasma
nmol/LEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Cmax after first dose61.3 ± 20.5240 ± 21.2592 ± 23.72670 ± 26.1
Cmax at steady-state (N=9,8,9,8)66.6 ± 26.7272 ± 30.1622 ± 17.42700 ± 20.9
Cmin at steady-state (N=9,8,9,8)4.41 ± 36.923.5 ± 31.547.1 ± 35.3243 ± 32.0
Cavg at steady-state (N=9,8,9,8)19.2 ± 24.383.5 ± 17.4204 ± 21.5922 ± 28.7
C24,8 (N=9,8,9,8)4.55 ± 36.823.8 ± 31.747.2 ± 35.2249 ± 27.6
Statistical analysis
  • Empagliflozin 2.5 mg qd vs Empagliflozin 100 mg qd · Regression, Linear · Geometric mean of ratio: 43.661 · 95% CI 27.520 to 69.269
  • Empagliflozin 2.5 mg qd vs Empagliflozin 100 mg qd · Regression, Linear · Geometric mean of ratio: 31.234 · 95% CI 12.193 to 80.011
SecondaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)

AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)
nmol*h/LEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
AUC0-∞ after first dose468 ± 19.61890 ± 14.74780 ± 23.723300 ± 19.4
AUC0-24 after first dose397 ± 17.61620 ± 13.54200 ± 23.619700 ± 17.6
AUC0-tau at steady state (N=9,8,9,8)460 ± 24.32000 ± 17.44890 ± 21.522100 ± 28.7
Statistical analysis
  • Empagliflozin 2.5 mg qd vs Empagliflozin 100 mg qd · Regression, Linear · Geometric mean of ratio: 49.707 · 95% CI 33.490 to 73.776
  • Empagliflozin 2.5 mg qd vs Empagliflozin 100 mg qd · Regression, Linear · Geometric mean of ratio: 37.632 · 95% CI 15.429 to 91.789
SecondaryTime to Maximum Concentration of the Analyte in Plasma

Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Median · h
Time to Maximum Concentration of the Analyte in Plasma
hEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
tmax after first dose1.50 ± 27.51.50 ± 18.21.50 ± 38.53.00 ± 77.8
tmax at steady-state (N=9,8,9,8)1.50 ± 27.41.50 ± 24.32.00 ± 62.61.50 ± 62.3
SecondaryTerminal Rate Constant in Plasma

Terminal rate constant in plasma after first dose and at steady-state

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · 1/h
Terminal Rate Constant in Plasma
1/hEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Terminal rate after first dose0.0618 ± 22.40.0586 ± 11.50.0654 ± 19.90.0527 ± 26.8
Terminal rate at steady-state (N=9,8,9,8)0.0686 ± 18.50.0491 ± 17.50.0658 ± 18.80.0409 ± 48.4
SecondaryHalf-life and Mean Residence Time of the Analyte in Plasma

Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · h
Half-life and Mean Residence Time of the Analyte in Plasma
hEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
t1/2 after first dose11.2 ± 22.411.8 ± 11.510.6 ± 19.913.2 ± 26.8
t1/2 at steady state (N=9,8,9,8)10.1 ± 18.514.1 ± 17.510.5 ± 18.817.0 ± 48.4
MRT po after first dose12.2 ± 12.412.1 ± 19.111.0 ± 13.512.7 ± 19.7
MRT po at steady-state (9,8,9,8)10.7 ± 14.213.5 ± 22.711.2 ± 13.714.6 ± 20.6
SecondaryApparent Volume of Distribution During the Terminal Phase

Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Phase
LEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Vz/F after first dose192 ± 27.2200 ± 19.5177 ± 27.9181 ± 35.1
Vz/F at steady state (N=9,8,9,8)176 ± 25.0225 ± 25.9172 ± 21.7245 ± 56.7
SecondaryAmount of Analyte Eliminated in Urine

Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)

Time frame:
0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Reported as:
Geometric mean · nmol
Amount of Analyte Eliminated in Urine
nmolEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Ae0-48 after first dose706 ± 24.72570 ± 42.25250 ± 52.018500 ± 32.7
Ae0-48 at steady-state (N=9,8,8,9)941 ± 32.14530 ± 23.58450 ± 42.722400 ± 145
Ae0-24 after first dose613 ± 26.92250 ± 42.74770 ± 54.616600 ± 34.3
Ae0-24 at steady-state (N=9,8,8,9)820 ± 33.94040 ± 26.77520 ± 43.619300 ± 153
SecondaryFraction of Analyte Excreted Unchanged in Urine

Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.

Time frame:
0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Reported as:
Geometric mean · percent of analyte
Fraction of Analyte Excreted Unchanged in Urine
percent of analyteEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
fe0-12 after first dose8.50 ± 31.98.43 ± 39.86.30 ± 78.26.17 ± 37.6
fe0-12 at steady-state (N=9,8,8,9)10.6 ± 47.014.7 ± 26.59.22 ± 54.06.68 ± 154
fe0-24 after first dose11.1 ± 26.910.1 ± 42.77.38 ± 73.07.48 ± 34.3
fe0-24 at steady-state (N=9,8,8,9)14.8 ± 33.918.2 ± 26.711.4 ± 53.68.71 ± 153
SecondaryApparent and Renal Clearance of the Analyte in Plasma

Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · mL/min
Apparent and Renal Clearance of the Analyte in Plasma
mL/minEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
CL/F after first dose198 ± 19.6195 ± 14.7193 ± 23.7159 ± 19.4
CL/F at steady-state (N=9,8,9,8)201 ± 24.3184 ± 17.4189 ± 21.5167 ± 28.7
CLR (0-48h) after first dose26.7 ± 42.923.5 ± 33.018.8 ± 53.113.9 ± 44.1
CLR (0-24h) at steady-state (N=9,8,8,9)29.7 ± 52.033.6 ± 24.921.7 ± 47.122.2 ± 83.3
SecondaryPeak Trough Fluctuation

Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · PTF(%) of Empagliflozin
Peak Trough Fluctuation
PTF(%) of EmpagliflozinEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Peak Trough Fluctuation323 ± 20.6294 ± 28.4281 ± 26.4265 ± 31.9
SecondaryLinearity Index

The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · Fraction
Linearity Index
FractionEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Linearity Index0.983 ± 8.421.05 ± 2.391.02 ± 11.40.962 ± 19.7
SecondaryAccumulation Ratios

Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau

Time frame:
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Reported as:
Geometric mean · Ratio
Accumulation Ratios
RatioEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Accumulation ratio based on Cmax1.09 ± 27.01.13 ± 20.91.05 ± 22.30.972 ± 36.8
Accumulated ratio based on AUC0-tau1.16 ± 8.391.23 ± 6.171.16 ± 11.91.12 ± 20.7
SecondaryChange From Baseline to Day 8 in Urinary Glucose Excretion

Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.

Time frame:
-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8
Reported as:
Mean · mg
Change From Baseline to Day 8 in Urinary Glucose Excretion
mgPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Change From Baseline to Day 8 in Urinary Glucose Excretion-3254.43 ± 8250.4334638.37 ± 16226.2278709.87 ± 53463.5274030.40 ± 35378.0188040.32 ± 20265.87
Statistical analysis
  • Placebo vs Empagliflozin 2.5 mg qd · ANCOVA · p = 0.0067 (This was non-confirmatory testing.) · Mean difference (final values): 37645.43 · 95% CI 11021.57 to 64269.30The baseline value has been used a continuous covariate.
  • Placebo vs Empagliflozin 10 mg qd · ANCOVA · p = <0.0001 (This was non-confirmatory testing.) · Mean difference (final values): 82898.20 · 95% CI 55344.83 to 110451.6Mean difference to placebo is calculated.
  • Placebo vs Empagliflozin 25 mg qd · ANCOVA · p = <0.0001 (This was non-confirmatory testing.) · Mean difference (final values): 79982.89 · 95% CI 53087.22 to 106878.6Mean Difference to placebo is calculated.
  • Placebo vs Empagliflozin 100 mg qd · ANCOVA · p = <0.0001 (This was non-confirmatory testing.) · Mean difference (final values): 91306.96 · 95% CI 64685.41 to 117928.5Mean Difference to placebo was calculated
SecondaryMean Daily Glucose

Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.

Time frame:
0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8
Reported as:
Mean · mg/dL
Mean Daily Glucose
mg/dLPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Mean Daily Glucose-13.85 ± 21.39-27.03 ± 24.59-34.04 ± 19.43-25.89 ± 18.00-30.96 ± 25.03
Statistical analysis
  • Placebo vs Empagliflozin 2.5 mg qd · ANCOVA · p = 0.0449 (This was non-confirmatory testing.) · Mean difference (final values): -15.456 · 95% CI -30.543 to -0.369Mean difference to placebo was calculated.
  • Placebo vs Empagliflozin 10 mg qd · ANCOVA · p = 0.0042 (This was non-confirmatory testing.) · Mean difference (final values): -23.467 · 95% CI -39.085 to -7.848Mean difference to placebo was calculated.
  • Placebo vs Empagliflozin 25 mg qd · ANCOVA · p = 0.0521 (This was non-confirmatory testing.) · Mean difference (final values): -14.956 · 95% CI -30.057 to 0.145Mean difference to placebo was calculated.
  • Placebo vs Empagliflozin 100 mg qd · ANCOVA · p = 0.1676 (This was non-confirmatory testing.) · Difference to placebo: -10.602 · 95% CI -25.848 to 4.644Mean difference to placebo was calculated
SecondaryFasting Plasma Glucose

Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.

Time frame:
-0:30 (Pre dose samples)
Reported as:
Mean · percentage of fasting plasma glucose
Fasting Plasma Glucose
percentage of fasting plasma glucosePlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Fasting Plasma Glucose-15.88 ± 12.88-21.01 ± 6.38-25.69 ± 9.88-14.21 ± 26.00-24.85 ± 8.18
Statistical analysis
  • Placebo vs Empagliflozin 2.5 mg qd · ANCOVA · p = 0.2239 (This was non-confirmatory testing.) · Mean difference (final values): -7.269 · 95% CI -19.162 to 4.624Mean difference to placebo was calculated.
  • Placebo vs Empagliflozin 10 mg qd · ANCOVA · p = 0.0421 (This was non-confirmatory testing.) · Mean difference (final values): -12.844 · 95% CI -25.205 to -0.484Mean difference to placebo was calculated
  • Placebo vs Empagliflozin 25 mg qd · ANCOVA · p = 0.6527 (This was non-confirmatory testing.) · Mean difference (final values): -2.719 · 95% CI -14.842 to 9.403Mean difference to placebo was calculated.
  • Placebo vs Empagliflozin 100 mg qd · ANCOVA · p = 0.1318 (This was non-confirmatory testing.) · Mean difference (final values): -8.998 · 95% CI -20.818 to 2.822Mean difference to placebo was calculated.
SecondarySerum Insulin

Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.

Time frame:
0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8
Reported as:
Mean · µU*h/mL
Serum Insulin
µU*h/mLPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
AUEC0-5 (12,9,9,9,9) on day-2134 ± 52.5185 ± 79.2175 ± 70.7137 ± 64.7119 ± 35.9
AUEC0-12 (12,9,9,9,9) on day-2300 ± 111474 ± 149471 ± 143336 ± 161282 ± 41.6
AUEC0-5 (11,9,8,9,9) on day8122 ± 52.0174 ± 80.9180 ± 74.7117 ± 103101 ± 37.2
AUEC0-12 (11,9,7,9,8) on day8288 ± 97.1417 ± 132387 ± 154266 ± 193275 ± 72.4
SecondarySerum Insulin

Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)

Time frame:
0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8
Reported as:
Mean · µU/mL
Serum Insulin
µU/mLPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
Emax,0-5 (12,9,9,9,9) on day-238.1 ± 17.355.2 ± 29.951.2 ± 23.440.2 ± 19.435.2 ± 15.5
Emax,0-12 (12,9,9,9,9) on day-245.4 ± 12.668.5 ± 25.372.1 ± 27.748.7 ± 30.945.3 ± 11.3
Emin,0-5 (12,9,9,9,9) on day-210.3 ± 5.4614.1 ± 5.4513.7 ± 4.629.16 ± 7.597.86 ± 2.18
Emin,0-12 (12,9,9,9,9) on day-29.98 ± 4.8614.1 ± 5.4513.5 ± 4.379.16 ± 7.597.86 ± 2.18
Emax,0-5 (11,9,8,9,9) on day835.6 ± 15.656.0 ± 32.156.3 ± 25.436.2 ± 37.329.6 ± 11.7
Emax,0-12 (11,9,8,9,9) on day842.6 ± 13.170.2 ± 26.168.6 ± 31.144.4 ± 35.537.3 ± 8.10
Emin,0-5 (11,9,8,9,9) on day87.55 ± 3.828.63 ± 3.3910.7 ± 5.605.33 ± 3.143.96 ± 2.79
Emin,0-12 (11,9,8,9,9) on day87.41 ± 3.908.53 ± 3.4610.7 ± 5.605.17 ± 3.193.96 ± 2.79

Adverse events

Collected over day1 to day21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/12 (0%)5/12 (41.7%)
Empagliflozin 2.5 mg qd—0/9 (0%)6/9 (66.7%)
Empagliflozin 10 mg qd—0/9 (0%)5/9 (55.6%)
Empagliflozin 25 mg qd—0/9 (0%)5/9 (55.6%)
Empagliflozin 100 mg qd—0/9 (0%)3/9 (33.3%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qd
HypoglycaemiaMetabolism and nutrition disorders0/120/92/91/90/9
HeadacheNervous system disorders1/120/91/92/90/9
ParaesthesiaNervous system disorders0/122/90/90/90/9
DiarrhoeaGastrointestinal disorders1/122/90/90/90/9
Arthropod stingInjury, poisoning and procedural complications0/120/90/92/90/9
CellulitisInfections and infestations0/120/91/90/90/9
NasopharyngitisInfections and infestations0/120/90/91/91/9
RhinitisInfections and infestations0/120/90/91/90/9
DizzinessNervous system disorders0/121/91/90/90/9
SciaticaNervous system disorders0/121/91/90/90/9

Baseline characteristics

Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(years)PlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qdTotal
Mean58.9 ± 6.453.9 ± 10.951.8 ± 10.758.9 ± 8.860.3 ± 5.656.9 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 2.5 mg qdEmpagliflozin 10 mg qdEmpagliflozin 25 mg qdEmpagliflozin 100 mg qdTotal
Female221229
Male10787739
08

Study locations

1 site
  • 1245.2.1 Boehringer Ingelheim Investigational Site
    Neuss, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2013
First posted
Aug 16, 2013
Start
Jul 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Jul 4, 2014
Last update
Jul 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01924767
Responsible party
Sponsor
First posted
Aug 16, 2013
Start date
Jul 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Jul 4, 2014
Last update
Jul 4, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion